Moffitt Cancer Center | Strategic Alliance Partnership
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 52 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 7,500 team members, Moffitt has an economic impact in the state of $2.4 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter, Instagram and YouTube.
Latest from Moffitt Cancer Center
Precision Medicine Can Close Oncology Gaps—and Lead to “Doing Less”
December 20th 2021Physicians said it is in payers’ interest to use artificial intelligence to address social determinants of health, to cover tests, and to gather data. Doing so could let them stratify who needs certain screenings and diagnostic procedures and who doesn’t, which could lead to less consumption of health care.
Read More
Dr Frederick Locke on Real-World Implications of ZUMA-7 Findings in Relapsed/Refractory LBCL
December 13th 2021Frederick Locke, MD, vice chair, Department of Blood and Marrow Transplant and Cellular Immunotherapy Program, co-leader, Immuno-Oncology, Moffitt Cancer Center, discusses findings of the phase 3 ZUMA-7 trial presented at ASH 2021 and how use of axicabtagene ciloleucel can be optimally applied in a real-world setting.
Watch
ZUMA-7: Axi-Cel in Second Line Is the “New Standard” in R/R LBCL, Locke Says
December 13th 2021Frederick L. Locke, MD, of Moffitt Cancer Center in Tampa, Florida, is the lead study author of the phase 3 ZUMA-7 trial, which examined the use of axi-cel in second-line treatment of patients with relapsed or refractory large B-cell lymphoma (R/R LBCL).
Read More
From Making Oncology Clinical Pathways Multidisciplinary, to Adding the Patient’s Voice
December 18th 2020According to the final panel at Patient-Centered Oncology Care®, clinical pathways can create a new problem: if each payer tries to impose its own pathways, it’s an administrative and ethical nightmare.
Read More
